Outcome of Board Meeting held on 13 th November 2025, as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kabra Drugs Ltd's board met on 13 November 2025 and approved the unaudited financial results for Q2 FY26 (quarter ended 30 September 2025) and the half-year, along with a limited review report from statutory auditors. The company swung to a strong profit, posting Q2 revenue of Rs 1,976.40 lakhs and a net profit of Rs 183.68 lakhs, versus a loss in the year-ago period. For H1 FY26, total income stood at Rs 2,710.88 lakhs with a net profit of Rs 133.70 lakhs (compared to a loss of Rs 94.24 lakhs in H1 FY25), and basic EPS of Rs 0.56. The board also reconstituted the composition of the board and its committees (Audit, NRC, Stakeholders Relationship) effective the same day, with Nanjappan Aravind continuing as Managing Director and Anand Anitha as Independent Director-Chairperson. Total assets grew sharply to Rs 5,450.18 lakhs as of 30 September 2025, mainly driven by inventory and trade receivables, though operating cash flow was negative at Rs (866.46) lakhs. The company also confirmed that Regulation 32 (use of proceeds reporting) is not applicable as no public/rights/preferential issue was made.
Strong turnaround in profitability with a swing from loss to profit and a sharp jump in revenue is a positive signal for shareholders, though the negative operating cash flow and ballooning working capital (inventory and receivables) warrant close monitoring. The board reconstitution appears routine with no change in leadership, suggesting stability.